Enovis Corporation (ENOV)Healthcare | Medical Devices | Wilmington, United States | NYSE
26.25 USD
+0.50
(1.942%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 26.77 +0.52 (1.981%) ⇧ (July 13, 2026, 7:56 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:01 a.m. EDT
The investment case here is fundamentally broken. Despite a forward P/E of 6.3 and a 'strong buy' analyst consensus, the company is hemorrhaging value with negative profit margins (-49.9%), negative ROE (-55%), and a trailing EPS of -$19.89. The market has correctly priced this as a deteriorating business; the stock is down nearly 30% over the last nine years, with the last two years seeing double-digit declines. There is no dividend to provide income, and the balance sheet carries significant debt against shrinking equity. While the stock trades near its book value, this is a value trap, not a bargain. The recent price spike appears to be a temporary anomaly driven by low float or specific news, as the underlying operational reality remains dire. Investors should avoid this security until there is clear evidence of a turnaround in profitability. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.059021 |
| AutoETS | 0.066277 |
| MSTL | 0.074314 |
| AutoTheta | 0.074607 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 54% |
| H-stat | 1.56 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.407 |
| Excess Kurtosis | -0.88 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 95.338 |
| Revenue per Share | 39.832 |
| Market Cap | 1,511,018,368 |
| Forward P/E | 6.43 |
| Beta | 1.50 |
| Profit Margins | -49.91% |
| Previous Name | Colfax Corporation |
| Website | https://www.enovis.com |
As of July 11, 2026, 3:01 a.m. EDT: Speculators are positioning defensively with heavy put volume relative to calls, particularly in the December 2026 expiration where out-of-the-money puts show significant open interest. Implied volatility is elevated on downside strikes compared to calls, suggesting a fear of further decline rather than an expectation of a rally. The lack of call volume at higher strikes indicates limited speculative appetite for a recovery.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.19430536 |
| Address1 | 2,711 Centerville Road |
| Address2 | Suite 400 |
| All Time High | 129.72461 |
| All Time Low | 9.173838 |
| Ask | 0.0 |
| Ask Size | 300 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,557,880 |
| Average Daily Volume3 Month | 1,166,826 |
| Average Volume | 1,166,826 |
| Average Volume10Days | 1,557,880 |
| Beta | 1.498 |
| Bid | 0.0 |
| Bid Size | 500 |
| Board Risk | 1 |
| Book Value | 25.662 |
| City | Wilmington |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 3 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 26.25 |
| Current Ratio | 2.037 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 27.08 |
| Day Low | 25.795 |
| Debt To Equity | 95.338 |
| Display Name | Enovis |
| Earnings Call Timestamp End | 1,778,157,000 |
| Earnings Call Timestamp Start | 1,778,157,000 |
| Earnings Timestamp | 1,778,157,000 |
| Earnings Timestamp End | 1,786,019,400 |
| Earnings Timestamp Start | 1,786,019,400 |
| Ebitda | 372,248,992 |
| Ebitda Margins | 0.16338 |
| Enterprise To Ebitda | 7.766 |
| Enterprise To Revenue | 1.269 |
| Enterprise Value | 2,890,981,376 |
| Eps Current Year | 3.64774 |
| Eps Forward | 4.07963 |
| Eps Trailing Twelve Months | -19.89 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 23.429 |
| Fifty Day Average Change | 2.8209991 |
| Fifty Day Average Change Percent | 0.12040629 |
| Fifty Two Week Change Percent | -19.430536 |
| Fifty Two Week High | 34.28 |
| Fifty Two Week High Change | -8.029999 |
| Fifty Two Week High Change Percent | -0.23424734 |
| Fifty Two Week Low | 19.14 |
| Fifty Two Week Low Change | 7.1100006 |
| Fifty Two Week Low Change Percent | 0.3714734 |
| Fifty Two Week Range | 19.14 - 34.28 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,210,253,400,000 |
| Float Shares | 56,585,190 |
| Forward Eps | 4.07963 |
| Forward P E | 6.434407 |
| Free Cashflow | 206,902,368 |
| Full Exchange Name | NYSE |
| Full Time Employees | 7,802 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.61000997 |
| Gross Profits | 1,389,835,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01625 |
| Held Percent Institutions | 1.21784 |
| Implied Shares Outstanding | 57,562,603 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,649,116,800 |
| Last Split Factor | 581:1000 |
| Long Business Summary | Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware. |
| Long Name | Enovis Corporation |
| Market | us_market |
| Market Cap | 1,511,018,368 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_617309 |
| Most Recent Quarter | 1,775,174,400 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -1,135,415,040 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,482,237,027 |
| Number Of Analyst Opinions | 11 |
| Open | 25.84 |
| Operating Cashflow | 242,840,000 |
| Operating Margins | 0.036429998 |
| Overall Risk | 1 |
| Payout Ratio | 0.0 |
| Peg Ratio | 3.45 |
| Phone | 302 252 9160 |
| Post Market Change | 0.52000046 |
| Post Market Change Percent | 1.9809542 |
| Post Market Price | 26.77 |
| Post Market Time | 1,783,987,001 |
| Prev Name | Colfax Corporation |
| Previous Close | 25.75 |
| Price Eps Current Year | 7.1962366 |
| Price Hint | 2 |
| Price To Book | 1.0229132 |
| Price To Sales Trailing12 Months | 0.66320264 |
| Profit Margins | -0.49915 |
| Quick Ratio | 0.784 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | 0.5 |
| Regular Market Change Percent | 1.94175 |
| Regular Market Day High | 27.08 |
| Regular Market Day Low | 25.795 |
| Regular Market Day Range | 25.795 - 27.08 |
| Regular Market Open | 25.84 |
| Regular Market Previous Close | 25.75 |
| Regular Market Price | 26.25 |
| Regular Market Time | 1,783,972,802 |
| Regular Market Volume | 754,345 |
| Return On Assets | 0.0109 |
| Return On Equity | -0.55347 |
| Revenue Growth | 0.054 |
| Revenue Per Share | 39.832 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 57,562,603 |
| Shares Percent Shares Out | 0.165 |
| Shares Short | 9,495,565 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 8,653,272 |
| Short Name | Enovis Corporation |
| Short Percent Of Float | 0.1967 |
| Short Ratio | 7.89 |
| Source Interval | 15 |
| State | DE |
| Symbol | ENOV |
| Target High Price | 55.0 |
| Target Low Price | 29.0 |
| Target Mean Price | 40.72727 |
| Target Median Price | 40.0 |
| Total Cash | 33,129,000 |
| Total Cash Per Share | 0.576 |
| Total Debt | 1,410,520,960 |
| Total Revenue | 2,278,365,952 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -19.89 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 25.7319 |
| Two Hundred Day Average Change | 0.51810074 |
| Two Hundred Day Average Change Percent | 0.02013457 |
| Type Disp | Equity |
| Volume | 754,345 |
| Website | https://www.enovis.com |
| Zip | 19,808 |